Innophore vc Deck 2024 Customer Segments Drug Design Repurposing

A pharmaceutical company can spend 10 to 15 years developing a single medicine, only to see it fail during testing. Industry estimates suggest that nearly 90% of drug candidates never reach commercialization because of safety concerns, lack of efficacy, or unexpected side effects.

As healthcare challenges continue to grow, pharmaceutical companies are looking for technologies that can improve research efficiency and reduce development risks.

This is where Innophore has built its position. The Austrian biotechnology company uses artificial intelligence and molecular intelligence technologies to help pharmaceutical companies, biotechnology firms, and research institutions discover and repurpose drugs faster.

According to WHO and UN Reports, Healthcare Innovation Has Never Been More Important

According to the World Health Organization (WHO), non-communicable diseases account for approximately 74% of all global deaths each year.

Cancer alone remains one of the leading causes of mortality worldwide. According to global health projections, annual cancer cases are expected to exceed 35 million by 2050, representing a significant increase from current levels.

At the same time, according to United Nations population estimates, the global population aged 65 years and older is expected to more than double between 2021 and 2050.

These trends are increasing the demand for new medicines while putting pressure on pharmaceutical companies to accelerate research and development.

Researchers are also dealing with massive amounts of biological data. Millions of protein structures and molecular datasets are now available, making traditional analysis methods increasingly difficult.

This growing complexity has created opportunities for AI-powered drug discovery platforms such as Innophore.

Turning Complex Protein Data into Faster Drug Discovery Decisions

Traditional drug discovery approaches often rely on laboratory testing and sequence-based protein analysis.

Innophore takes a different route through its proprietary Catalophore™ technology. Instead of focusing only on protein sequences, the platform analyzes the physical and chemical properties of protein binding sites.

This allows researchers to identify biologically similar proteins that may appear unrelated through conventional analysis methods.

Think of it as comparing the shape of locks rather than simply comparing the keys.

By understanding how molecules interact inside biological systems, researchers can identify potential drug targets more quickly and accurately.

Customer Segment 1: Pharmaceutical Companies Focused on Drug Design

Pharmaceutical companies represent one of Innophore’s largest customer groups.

These organizations invest billions of dollars annually in research and development while facing significant pressure to improve productivity.

According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the global pharmaceutical sector invests more than €270 billion every year in research and development activities.

Innophore’s platform helps researchers identify promising drug candidates earlier in the development process.

Using artificial intelligence and high-performance computing systems, the company can perform millions of molecular calculations daily. This allows pharmaceutical researchers to evaluate potential compounds much faster than traditional screening methods.

As a result, pharmaceutical companies can potentially reduce development timelines while improving candidate selection.

Customer Segment 2: Drug Repurposing Teams Looking for Hidden Opportunities

Drug repurposing has emerged as one of the most efficient strategies in modern drug development.

Instead of developing a completely new medicine, researchers identify additional uses for drugs that already exist.

According to the U.S. Food and Drug Administration (FDA), repurposed drugs often benefit from previously established safety and clinical data, helping reduce both risk and development costs.

During the COVID-19 pandemic, Innophore conducted large-scale drug repurposing projects using artificial intelligence.

Its platform screened thousands of protein targets and analyzed known compounds to identify potential therapeutic opportunities.

For pharmaceutical companies, this approach can shorten development timelines and improve return on research investments.

Customer Segment 3: Biotechnology Companies and Research Organizations

Biotechnology companies and research institutions form another important customer segment.

Many of these organizations focus on enzymes, biologics, rare diseases, protein engineering, and precision medicine.

They require advanced computational technologies to understand complex biological interactions and identify novel opportunities.

Innophore’s platform enables researchers to discover protein relationships that may not be visible through traditional sequence-based methods.

This capability is particularly valuable for organizations working on next-generation therapeutics and innovative biotechnology solutions.

As biological datasets continue expanding, AI-powered analysis tools are becoming increasingly important across the biotechnology industry.

Customer Segment 4: Drug Safety and Off-Target Screening Teams

Drug safety remains one of the most important priorities during pharmaceutical development.

Unexpected interactions with unintended biological targets are responsible for many late-stage development failures.

According to FDA safety assessments, adverse drug reactions continue to create major healthcare and financial burdens worldwide.

Innophore’s platform helps researchers identify potential off-target interactions before compounds enter expensive clinical testing phases.

In large-scale validation studies involving hundreds of drug targets, the company’s technology successfully identified a significant number of experimentally confirmed alternative targets among its highest-ranked predictions.

Earlier identification of safety risks can help pharmaceutical companies save substantial development costs while improving success rates.

Companies, Investments, and Computing Power Driving AI Drug Discovery

Innophore operates within a rapidly growing AI drug discovery ecosystem alongside companies such as Insilico Medicine, Recursion Pharmaceuticals, Exscientia, Iambic Therapeutics, and Schrödinger.

The scale of investment in this industry continues to rise. Recursion Pharmaceuticals has invested heavily in AI infrastructure and operates one of the world’s largest biological datasets. Insilico Medicine became one of the first companies to advance an AI-discovered drug candidate into human clinical trials.

Innophore has also demonstrated significant computational capabilities.

The company has analyzed more than 42,000 human proteins, utilized over 270,000 GPU computing hours, and performed millions of molecular calculations daily. Certain computational tasks that previously required approximately 2,000 hours can now be completed in as little as 15 minutes using advanced AI infrastructure.

These improvements highlight how artificial intelligence is transforming pharmaceutical research and accelerating scientific discovery.

Key Technology Metrics

Innophore’s customer strategy focuses on solving one of the biggest challenges in healthcare: reducing the time and cost required to discover new medicines.

The company serves pharmaceutical organizations designing new drugs, drug repurposing teams searching for additional therapeutic uses, biotechnology firms developing innovative therapies, and safety specialists evaluating potential risks.

According to global healthcare forecasts, demand for new treatments will continue increasing as populations age and chronic diseases become more common.

In this environment, technologies that improve research productivity and accelerate decision-making are becoming increasingly valuable.

For Innophore, success is not only about artificial intelligence. It is about helping scientists understand complex molecular relationships faster, allowing better therapies to reach patients sooner and improving the future of healthcare innovation.

Get Easy Access